[China Pharmaceutical Network Technology News] Faced with a growing number of complex diseases and patients, the time and money defects of new drug development are far from meeting the needs of the current medical industry, and the development of new drugs urgently needs to be automated. The precise design of the robot will drive the realization of the automation of the new drug development process. 
The robot will help boost the automation of the new drug development process
When people talk about the robot industry, they think of robots as "alternatives". However, in the view of robot expert Xi Ning, this view is not comprehensive. He believes that the application of robots is actually an extension of human capabilities. Recently, Xi Ning, an outstanding professor of the Department of Electrical and Computer Engineering at the Michigan State University and the deputy director of the Academic Committee of the Shenyang Institute of Automation, Chinese Academy of Sciences, who came back from the United States to participate in the robot conference that just came to a close, said in an interview with the reporter: "Following the automobile industry After that, new drug development will become the next industrial field for robots to enter."
“When robots first appeared, the main purpose was to replace people with repetitive and unwilling work. However, with the development of information technology, biotechnology and nanotechnology, especially network technology, big data, cloud computing, etc. With the development of technology, robots can expand the capabilities that people don't have, and can help humans do things they can't do."
Xi Ning told reporters that the development of the robot industry is driven by the promotion of new technologies and the application of new applications. Among them, the application of nano-robots in the field of biomedicine will become the next explosion point.
“The most successful application areas for robotics are manufacturing, especially in the automotive industry. 90% of industrial robots are used in the automotive manufacturing process. The value of biomedical applications is much larger than in the automotive industry, but in the development of new drugs, Many processes are artificial.†Xi Ning said, “Technical workers who assemble cars can do it, and new drug development has high requirements for practitioners and high development costs. Therefore, it is very important to automate the process of new drug development. ."
“At present, the degree of automation of new drug development is very low, and the potential value space is very large. If robots and automation can be successfully used for new drug development, it will produce such a large application as today's automobile industry, which can create value of 560 billion yuan.†Xi Ning said.
According to him, it takes 10-15 years to develop a new drug, which will cost 10 to 1.5 billion US dollars. At present, Pfizer, the world's largest R&D-based biopharmaceutical company, can only develop 1-2 new drugs every year, and it costs a lot. The reality is that humans are still experiencing new diseases. "There are more and more diseases, the cost of developing drugs is getting higher and higher, and the emergence of new drugs is relatively less and less. This is a huge challenge for human beings. The important way to solve this problem is to automate the process of developing new drugs. The benefits and social values ​​will be very high." Xi Ning said.
Despite the huge market opportunities, Xi Ning said that the problems and challenges of using robots in the development of new drugs are also very difficult. “For example, scientists also need to solve the problem of sensing and sensing in a physiological environment.†He said, “In the development of new drugs, measuring drug efficacy is a process of perception. In addition, control issues are also important – parts inside the car are It is designed by people, the same size, error but small, is a structural environment, it is very beneficial for the robot to do high-speed repetitive work, but in the process of new drug development, it is necessary to test on the cells, each cell The shapes are different, the location is different, and it is a non-structural environment. How to accurately control the robot in such an environment is an important technical problem for successfully using the robot for new drug development."
“Nanobots can sense and control in a small environment, overcome the difficulties caused by scale and environment, and then operate and control. Make humans make a difference in the space we can't see.†Say, "In addition to the widespread use of robots in our living environment, we take another step. In an environment that we can't see or touch, robots can also play a big role and create great value. , making a great contribution to mankind."
What makes Xi Ning feel gratified is that with the further development of robot technology, micro-nano robots are gradually showing unprecedented advantages in the development of new drugs, and China has made significant progress in the research and development of nano-robots. It is understood that under the direct leadership of Xi Ning, the Shenyang Institute of Automation of the Chinese Academy of Sciences established a nano-robot research team and laboratory several years ago, and cooperated with the Shanghai Institute of Materia Medica and the Academy of Military Medical Sciences of the Chinese Academy of Sciences to develop the application of nano-robot in new drug development. .
Last year, with the strong support of the Shenzhen Science and Technology Innovation Committee, Xi Ning's team set up the Shenzhen Intelligent Robot Research Institute in Shenzhen, which is gradually promoting the industrialization of nano-robots.
"Industrial robots in western developed countries started earlier and the technology is relatively mature. Although China has just started in this respect, with the continuous application of the robot industry in emerging fields, everyone is standing on the same starting line, China will not let Others are holding their noses. We must seize the opportunity to become the leader in the future world robot industry in this new application field." Xi Ning said.
The robot will help boost the automation of the new drug development process
When people talk about the robot industry, they think of robots as "alternatives". However, in the view of robot expert Xi Ning, this view is not comprehensive. He believes that the application of robots is actually an extension of human capabilities. Recently, Xi Ning, an outstanding professor of the Department of Electrical and Computer Engineering at the Michigan State University and the deputy director of the Academic Committee of the Shenyang Institute of Automation, Chinese Academy of Sciences, who came back from the United States to participate in the robot conference that just came to a close, said in an interview with the reporter: "Following the automobile industry After that, new drug development will become the next industrial field for robots to enter."
“When robots first appeared, the main purpose was to replace people with repetitive and unwilling work. However, with the development of information technology, biotechnology and nanotechnology, especially network technology, big data, cloud computing, etc. With the development of technology, robots can expand the capabilities that people don't have, and can help humans do things they can't do."
Xi Ning told reporters that the development of the robot industry is driven by the promotion of new technologies and the application of new applications. Among them, the application of nano-robots in the field of biomedicine will become the next explosion point.
“The most successful application areas for robotics are manufacturing, especially in the automotive industry. 90% of industrial robots are used in the automotive manufacturing process. The value of biomedical applications is much larger than in the automotive industry, but in the development of new drugs, Many processes are artificial.†Xi Ning said, “Technical workers who assemble cars can do it, and new drug development has high requirements for practitioners and high development costs. Therefore, it is very important to automate the process of new drug development. ."
“At present, the degree of automation of new drug development is very low, and the potential value space is very large. If robots and automation can be successfully used for new drug development, it will produce such a large application as today's automobile industry, which can create value of 560 billion yuan.†Xi Ning said.
According to him, it takes 10-15 years to develop a new drug, which will cost 10 to 1.5 billion US dollars. At present, Pfizer, the world's largest R&D-based biopharmaceutical company, can only develop 1-2 new drugs every year, and it costs a lot. The reality is that humans are still experiencing new diseases. "There are more and more diseases, the cost of developing drugs is getting higher and higher, and the emergence of new drugs is relatively less and less. This is a huge challenge for human beings. The important way to solve this problem is to automate the process of developing new drugs. The benefits and social values ​​will be very high." Xi Ning said.
Despite the huge market opportunities, Xi Ning said that the problems and challenges of using robots in the development of new drugs are also very difficult. “For example, scientists also need to solve the problem of sensing and sensing in a physiological environment.†He said, “In the development of new drugs, measuring drug efficacy is a process of perception. In addition, control issues are also important – parts inside the car are It is designed by people, the same size, error but small, is a structural environment, it is very beneficial for the robot to do high-speed repetitive work, but in the process of new drug development, it is necessary to test on the cells, each cell The shapes are different, the location is different, and it is a non-structural environment. How to accurately control the robot in such an environment is an important technical problem for successfully using the robot for new drug development."
“Nanobots can sense and control in a small environment, overcome the difficulties caused by scale and environment, and then operate and control. Make humans make a difference in the space we can't see.†Say, "In addition to the widespread use of robots in our living environment, we take another step. In an environment that we can't see or touch, robots can also play a big role and create great value. , making a great contribution to mankind."
What makes Xi Ning feel gratified is that with the further development of robot technology, micro-nano robots are gradually showing unprecedented advantages in the development of new drugs, and China has made significant progress in the research and development of nano-robots. It is understood that under the direct leadership of Xi Ning, the Shenyang Institute of Automation of the Chinese Academy of Sciences established a nano-robot research team and laboratory several years ago, and cooperated with the Shanghai Institute of Materia Medica and the Academy of Military Medical Sciences of the Chinese Academy of Sciences to develop the application of nano-robot in new drug development. .
Last year, with the strong support of the Shenzhen Science and Technology Innovation Committee, Xi Ning's team set up the Shenzhen Intelligent Robot Research Institute in Shenzhen, which is gradually promoting the industrialization of nano-robots.
"Industrial robots in western developed countries started earlier and the technology is relatively mature. Although China has just started in this respect, with the continuous application of the robot industry in emerging fields, everyone is standing on the same starting line, China will not let Others are holding their noses. We must seize the opportunity to become the leader in the future world robot industry in this new application field." Xi Ning said.
The United States Food and Drug Administration (FDA) has published the Dietary Supplement Health and Education Act (DSHEA), which provides for dietary supplements. A product (other than tobacco) intended to supplement the diet may contain one or more of the following dietary ingredients: A vitamin, a mineral, an herb (herbal) or other plant, an amino acid, a food component used to increase the total daily intake to supplement the diet, or a concentrate, metabolite, component, extract or combination of the above ingredients, etc. It also includes approved new drugs, vitamins or biologics that have been marketed as dietary supplements or food products before they are approved, issued or licensed. The DSHEA defines dietary supplements as their composition and labeling requirements: the product form may be pill, capsule, tablet or liquid; The product shall not be used as a substitute for ordinary foods or as an exclusive dietary item. The product shall be labeled as a "dietary supplement".
Dietary Supplements,Arachidonic Acid Powder,Kava Root Powder,Kava Root Extract Powder
Xi'an Double H Health Technology Co., Ltd , https://www.xahnhcj.com